Terminal
Infiniti Feed

Clinical trial markets bring regulatory outcomes into sharper enforcement focus

Hogan Lovells reports Kalshi launched a pilot suite of prediction markets on clinical trial outcomes and FDA regulatory decisions in July 2026, while the CFTC and SEC issued a joint request for public comment and federal authorities began investigating and charging insider trading on the platforms. The analysis cites Pew Research Center figures putting combined Kalshi and Polymarket volume at nearly 24 billion dollars in April 2026.

Prediction markets are moving into clinical trial results and FDA decisions as authorities increase scrutiny of insider trading on the platforms, according to Hogan Lovells. The expansion places healthcare events alongside a growing debate over oversight of event contracts.

Healthcare contracts enter the market

Kalshi introduced a pilot suite of markets covering clinical trial outcomes and FDA regulatory decisions in July 2026, according to the Hogan Lovells analysis. The launch extends event-based trading to questions about trial results and regulatory action.

The analysis cites Pew Research Center figures showing combined Kalshi and Polymarket volume of nearly 24 billion dollars in April 2026. That figure covers the two platforms together; it is not a measure of trading in healthcare contracts.

Oversight advances on two fronts

According to Hogan Lovells, the CFTC and SEC issued a joint request for public comment. Alongside that regulatory process, federal authorities began investigating and charging insider trading on prediction-market platforms.

Those developments distinguish two aspects of oversight: public input sought by the agencies and enforcement activity by federal authorities. The supplied summary does not identify the subjects of the investigations or charges, or connect them specifically to Kalshi’s healthcare pilot.

What it means for prediction markets

  • New event categories: Kalshi’s July 2026 pilot adds clinical trial outcomes and FDA decisions to the questions prediction-market participants can trade.
  • Enforcement is already active: The reported investigations and charges make insider-trading scrutiny a present issue, rather than solely a question for future regulation.
  • Scale needs context: The nearly 24 billion dollars in April 2026 volume reflects combined Kalshi and Polymarket activity, not demand for the later healthcare pilot.
  • Rulemaking remains distinct from enforcement: The joint CFTC–SEC request seeks public comment; the summary does not establish any resulting policy change.
KalshiPolymarketSECCFTCInfiniti MarketsInfiniti Signals

Sources & attribution

Published
  1. Source
    Hogan Lovells
    Publisher
    The publisher did not list a web address.
    Source URL
    The feed did not publish this story's article address.

Full attribution under the Digital Millennium Copyright Act (DMCA), 17 U.S.C. § 512: this article is an original report by Infiniti Intelligence that summarizes the reporting of the publishers named above, links to their original work, and reproduces no protected expression beyond brief factual reference and in-line attribution (“according to Hogan Lovells”). All rights in the underlying reporting remain with the publishers listed; nothing here implies endorsement by or affiliation with them. Rights holders may request correction, update or removal through the contact address published at infiniti.w3ai.io.

Related